Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
HIV-1 genotypic profiling ensures effective response to third-line antiretroviral therapy in Cameroon.
Mbouyap PR, Fokam J, Ngoufack Jagni Semengue E, Mossiang L, Takou D, Ambe Chenwi C, Nka AD, Dambaya B, Teto G, Angong Beloumou G, Djupsa Ndjeyep SC, Ka'e AC, Kouanfack C, Ndjolo A, Mbopi Keou FX. Mbouyap PR, et al. Medicine (Baltimore). 2023 Jun 2;102(22):e33897. doi: 10.1097/MD.0000000000033897. Medicine (Baltimore). 2023. PMID: 37266631 Free PMC article.
Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
Ciaffi L, Koulla-Shiro S, Sawadogo AB, Ndour CT, Eymard-Duvernay S, Mbouyap PR, Ayangma L, Zoungrana J, Gueye NFN, Diallo M, Izard S, Bado G, Kane CT, Aghokeng AF, Peeters M, Girard PM, Le Moing V, Reynes J, Delaporte E; MOBIDIP study group. Ciaffi L, et al. Among authors: mbouyap pr. Lancet HIV. 2017 Sep;4(9):e384-e392. doi: 10.1016/S2352-3018(17)30069-3. Epub 2017 May 28. Lancet HIV. 2017. PMID: 28566227 Clinical Trial.